Tourette Syndrome — Viva

Q1: An 8-year-old boy has had eye-blinking, facial grimacing, head-jerking, throat-clearing and sniffing for 14 months, with onset before 18. Take me through the diagnosis and the DSM-5 criteria. (2 min)

This is Tourette syndrome (Tourette disorder) — a childhood-onset neurodevelopmental disorder at the most severe end of the tic-disorder spectrum. He fulfils all five DSM-5 criteria:^[1][8]

1. Multiple motor tics (eye-blinking, facial grimacing, head-jerking) plus one or more vocal (phonic) tics (throat-clearing, sniffing) — not necessarily concurrent.
2. Tics are present during the illness, though not necessarily every day.
3. Duration over 1 year (14 months) with no tic-free period exceeding 3 months.
4. Onset before 18 years.
5. Not attributable to a substance or another medical condition.

A tic is a sudden, rapid, recurrent, non-rhythmic motor movement or vocalisation that is temporarily suppressible and preceded by a premonitory urge (a building internal sensation that the tic transiently relieves). Coprolalia is NOT required for the diagnosis and affects only 8 to 15 percent of patients — a popular misconception. Tics wax and wane, worsen with stress/anxiety/caffeine, and diminish during sleep and focused activity.^[8]

Q2: Walk me through the pathophysiology. Why do antipsychotics work, and why does Tourette travel with OCD? (3 min)

Tourette syndrome is a disorder of the cortico-striato-thalamo-cortical (CSTC) loops. Three converging mechanisms explain the phenotype:^[1][4]

1. Basal-ganglia inhibitory failure. The striatum (caudate, putamen) normally gates competing motor programmes through its direct (D1, Go) and indirect (D2, No-Go) output pathways onto the globus pallidus internus / substantia nigra pars reticulata (GPi/SNr), which in turn inhibits the thalamus. In TS there is relative over-activity of the direct pathway and under-activity of the indirect pathway, so the GPi/SNr under-inhibits the thalamus and excessive excitatory thalamocortical drive reaches the supplementary motor area (SMA) and motor cortex — allowing unwanted motor programmes (tics) to escape. Structural imaging shows reduced caudate/putamen volumes, and post-mortem studies show reduced striatal GABAergic interneurons.

2. Dopaminergic dysregulation. There is increased phasic dopamine release in the striatum and D2-receptor supersensitivity. This is the pharmacological anchor: D2-blocking antipsychotics (haloperidol, risperidone, aripiprazole, pimozide) reliably reduce tic severity, while dopamine agonists can worsen tics. It is also why Huntington chorea (a hyperkinetic movement disorder) shares this dopaminergic-excess logic and responds to D2 blockers.

3. Sensorimotor/interoceptive dysfunction — the premonitory urge. Functional imaging shows abnormal activity in the SMA, anterior cingulate cortex (ACC), insula and somatosensory cortex. The premonitory urge is a building interoceptive sensation localised to the region of the impending tic; performing the tic transiently relieves it, which acts as a negative reinforcer — operantly strengthening the tic. This urge-tic-relief loop is the explicit target of Habit Reversal Training: substituting an incompatible competing response discharges the urge without performing the tic.

Why Tourette travels with OCD: both disorders involve the same CSTC loops — OCD weighted toward cortico-striatal affective/limbic loops and Tourette toward motor loops. The shared dopaminergic and CSTC-loop biology explains why OCD occurs in 30 to 50 percent of patients with Tourette and why the two disorders co-segregate in families.^[1]

Q3: What is your diagnostic and severity-assessment strategy? (2 min)

The diagnosis is clinical — there is no confirmatory laboratory test. I take a focused history of age of onset, body regions involved, motor versus vocal tics, the waxing/waning pattern, suppressibility, and the premonitory urge. I directly observe the tics and request home video recordings, since tics may be suppressed in clinic.^[1]

I grade severity with the Yale Global Tic Severity Scale (YGTSS), which has three components and a total of 0 to 100:^[1][4]

• Motor Tic Score (0 to 25) = number + frequency + intensity + complexity + interference (each 0 to 5).
• Vocal Tic Score (0 to 25) — same five dimensions for vocal tics.
• Global Impairment (0 to 50) — overall impact on self-esteem, family, social, school/occupational functioning.

I then screen every patient for the comorbidities that drive most of the impairment: ADHD (Conners-3, Vanderbilt), OCD (CY-BOCS / Y-BOCS), anxiety (GAD-7), depression (PHQ-9), rage attacks, sleep disturbance and learning difficulties. Investigations are needed only to exclude mimics when the presentation is atypical — ASO titre and anti-DNase B (PANDAS), copper/caeruloplasmin/Kayser-Fleischer rings (Wilson), HTT CAG repeat (Huntington), and MRI brain only for focal neurological signs, adult onset or a progressive course.^[4]

Q4: Walk me through your management. How do you choose between behavioural therapy, alpha-2 agonists and antipsychotics? (3 min)

Treatment is stepwise and severity-driven, with the explicit principle that the least impactful effective intervention should be used, and that the comorbidity is often treated first:^[2][3]

• Step 1 — Education, reassurance and school accommodations for mild, non-impairing tics. Most children need no medication.
• Step 2 — CBIT / Habit Reversal Training is first-line for impairing tics. Awareness training + competing response + relaxation + contingency management. Piacentini et al. JAMA 2010 showed a 24.7 percent YGTSS reduction versus 7.6 percent with supportive therapy — comparable to medication, without side effects.
• Step 3 — Alpha-2 adrenergic agonists are first-line DRUG. Clonidine 0.05 to 0.3 mg/day PO (or transdermal patch) OR guanfacine ER 1 to 4 mg/day PO — chosen because they ALSO treat comorbid ADHD and carry far less risk than antipsychotics. Monitor blood pressure and heart rate.
• Step 4 — Antipsychotic, for severe tics. Aripiprazole 2 to 20 mg/day PO is the preferred first antipsychotic (2022 European guideline; 2023 Farhat network meta-analysis) — best efficacy-tolerability balance, partial D2 agonist, less weight gain/EPSE than risperidone; main side effect is akathisia. Risperidone 0.25 to 3 mg/day PO is the best-evidenced alternative. Haloperidol is FDA-approved but rarely first-line. Baseline and periodic monitoring of weight, BMI, glucose, lipids, ECG, prolactin and EPSE/AIMS.
• Step 5 — Botulinum toxin A for focal disabling tics (dystonic neck-jerking, eye-blinking, vocal tics).
• Step 6 — Deep brain stimulation ONLY for severe refractory ADULT TS (failed behavioural + at least 2 drugs), multidisciplinary assessment and registry.^[5]

The key principle: treat the most impairing condition first. If ADHD is the dominant impairment, methylphenidate (which does NOT significantly worsen tics per the Tourette Syndrome Study Group 2002 trial) or atomoxetine is appropriate; an alpha-2 agonist treats both.^[3]

Q5 (examiner's probe): His parents have read online that stimulants cause tics and refuse methylphenidate for his ADHD. How do you counsel them?

I would explain the Tourette Syndrome Study Group 2002 randomised trial (JAMA), which demonstrated that methylphenidate did NOT significantly worsen tics when used to treat comorbid ADHD in children with Tourette syndrome — overturning the older dogma that stimulants were contraindicated in TS. ADHD is present in about 60 percent of patients with Tourette and is usually the most functionally impairing comorbidity, so leaving it untreated would itself cause substantial harm (academic underachievement, injury risk, low self-esteem).^[1][3]

Practically I would: (1) start with an alpha-2 agonist (clonidine or guanfacine), which treats both tics and ADHD — a sensible single drug when both coexist; (2) if ADHD remains impairing, carefully trial methylphenidate (or atomoxetine as a non-stimulant alternative) with monitoring of tic severity at each visit; (3) reassure the parents that even if an individual patient's tics transiently worsen, this is reversible on dose reduction or cessation. The principle is individualised, monitored prescribing, not blanket avoidance.

Q6 (final probe): A 19-year-old female influencer presents with abrupt-onset complex coprolalia-predominant tics after watching TikTok videos of people with Tourette. How does this differ, and why does it matter?

This is functional (psychogenic) tic-like disorder — the so-called "TikTok tics" first recognised in large numbers during the COVID-19 pandemic. It differs from Tourette syndrome on several discriminating features:^[1]

• Onset: sudden adolescent/young-adult female onset (vs the 5 to 7 year slow accrual of Tourette).
• Phenomenology: complex, coprolalia-predominant, dramatic, atypical tics (vs simple head/neck motor tics that march caudally over years in Tourette).
• Premonitory urge: ABSENT (vs present in most Tourette patients over 10).
• Waxing/waning: ABSENT; tics are context-bound — present only with an audience.
• Childhood history: none, and no comorbid ADHD (vs Tourette's strong childhood/ADHD/OCD background).

Why it matters: functional tic-like disorder is managed with cognitive behavioural therapy for functional neurological disorder (often with physiotherapy) — NOT with antipsychotics, which would expose the patient to EPSE, metabolic risk and tardive dyskinesia without benefit. Misdiagnosis as Tourette syndrome leads to incorrect, potentially harmful treatment. The same principle applies to adult-onset tics generally: always exclude drug-induced (stimulants, neuroleptic-induced tardive tics), neurodegenerative (Huntington, Wilson) and structural causes before attributing new adult-onset tics to Tourette.^[1]

References7ShowHide

1. [1]Johnson KA, Worbe Y, Foote KD. Tourette syndrome: clinical features, pathophysiology, and treatment. Lancet Neurology, 2023.PMID 36354027
2. [2]Müller-Vahl KR, Szejko N, Verdellen C, et al. European clinical guidelines for Tourette syndrome and other tic disorders: summary statement and recommendations. European Child and Adolescent Psychiatry, 2022.PMID 34244849
3. [3]Pringsheim T, Okun MS, Müller-Vahl K, et al. Practice guideline recommendations summary: Treatment of tics in people with Tourette syndrome and chronic tic disorders. Neurology, 2019.PMID 31061208
4. [4]Singer HS. Tics and Tourette Syndrome. Continuum (Minneapolis, Minn.), 2019.PMID 31356288
5. [5]Schrock LE, Mink JW, Woods DW, et al. Tourette syndrome deep brain stimulation: a review and updated recommendations. Movement Disorders, 2015.PMID 25476818
6. [8]Robertson MM. A personal 35 year perspective on Gilles de la Tourette syndrome: prevalence, phenomenology, comorbidities, and clinical management. Lancet Psychiatry, 2015.PMID 26359614
7. [9]Farhat LC, Behling E, Landeros-Weisenberger A, et al. Comparative efficacy, tolerability, and acceptability of pharmacological interventions for Tourette's disorder: a systematic review and network meta-analysis. Lancet Child and Adolescent Health, 2023.PMID 36528030